Description: Sarah Rockhill, MPH, Geospatial Epidemiologist at CDC will discuss the latest in the Public Health 3.0 model in which leaders serve as Chief Health Strategists, partnering across multiple sectors and leveraging data and resources to address social, environmental, and economic conditions that affect health and health equity.

Description: Value-based care (VBC) arrangements have grown exponentially in recent years with an expectation that this shift will only continue across the health care industry. CMS has set the goal of having 100% of traditional Medicare and the vast majority of Medicaid beneficiaries in accountable care relationships by 2030.

Description: Virtual - Session 1D: Pharmacy Risk Mitigation - Pricing, Programs, Pools, and Performance Guarantees

Description: Session 4C: The Impact of Medical Advancements on Disability and Group Life

Description: Session 10B: Comprehensive PBM Performance Evaluations Including TCOC Impact

Description: It happens every year: hurricanes, wildfires, and floods destroy property, interrupt routine care, and exacerbate chronic conditions. Clearly, general insurance and health actuaries need to reflect these conditions in their pricing projections even though there are lots of unanswered questions about the frequency, intensity, and location of significant events. In this session, the presenters will discuss how to reflect the impact of climate change in the day-to-day work of health and general insurance actuaries. After this session, attendees will be able to: - Describe the impact of climate change on property damage and healthcare - Identify relevant data sources and methods needed to reflect the impact of climate change for use in the day-to-day work of health and general insurance actuaries - Discuss the risk associated with climate change

Description: Actuaries historically modeled new launches in pharmaceuticals by anticipating the expected change to the market basket. This became more complicated with the recent launches of gene and cell therapies as they address rare diseases. Rare conditions have low total member volume to study and some do not currently have a diagnosis code to identify them within claims data. Addressing this modeling challenge has been growing more important in the recent years with the number of therapies launching. What has the health care industry, and more specifically health care, done to enhance modeling and how should this be altered for the future? Additionally, historic modeling has sometimes incorporated a level of direct medical treatment cost offsets where studies have shown lower treatment costs are achievable. Can gene and cell financial modeling include cost offsets as well? And if so, what are suggested precautions or limitations to this effort?

Description: Enjoy an in-depth walkthrough of the facets of the lab testing world in this webcast. The agenda will include a discussion on genetic testing, which focuses on its general background, current trends and tests in the pipeline, as well as a focus on the approaches to achieve savings in lab testing. Finally, expect to check out sample actuarial analyses that will be used to identify areas of focus in lab management. Join us and take a deeper look into lab work in the actuarial health industry.

Description: Discover a comparison of U.S. and international mandated leave programs which mandate employers to provide a minimum level of benefits to employees for qualifying leaves of absence, such as parental leave or medical leave.

Description: Cover a variety of topics centered around the unsupervised learning technique called 'clustering'. The presenters will take you through a wide array of topics that range from 'What is Clustering?' to 'How can I use this technique to solve problems I didn't even know existed?' In the health care industry, everyone is looking for an edge in reducing total spend-cluster analysis finds the unambiguous in an ambiguous framework of results.